Mark Wrona

887 citations

33 papers · 642 indexed · h-index 13

Impact in

Spectroscopy top 5%
- Analytical Chemistry and Chromatography
- Mass Spectrometry Techniques and Applications
- Advanced Proteomics Techniques and Applications
Pharmacology top 10%
- Inflammatory mediators and NSAID effects
- Pharmacogenetics and Drug Metabolism

Papers in ⓘ

Spectroscopy 12
- Analytical Chemistry and Chromatography 9
- Mass Spectrometry Techniques and Applications 9
Complementary and alternative medicine 5
- Traditional Chinese Medicine Analysis 3

Co-authors: Kevin P. Bateman (3 shared papers)Kate Yu (3 shared papers)Russell J. Mortishire‐Smith (3 shared papers)Renata M. Oballa (1 shared paper)José Castro‐Perez (1 shared paper)Deborah A. Nicoll‐Griffith (1 shared paper)John P. Shockcor (1 shared paper)Timo Mauriala (1 shared paper)
Journals: Planta Medica (6 papers)Bioanalysis (6 papers)Rapid Communications in Mass Spectrometry (4 papers)Bioorganic & Medicinal Chemistry Letters (4 papers)Drug Metabolism and Pharmacokinetics (2 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Mark Wrona

33 papers receiving 609 citations

Peers

Countries citing papers authored by Mark Wrona

Since Specialization

Citations

This map shows the geographic impact of Mark Wrona's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Wrona with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Wrona more than expected).

Fields of papers citing papers by Mark Wrona

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Wrona. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Wrona. The network helps show where Mark Wrona may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Wrona, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Wrona Line = papers co-authored together Mark Wrona links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	MS ^E with mass defect filtering for in vitro and in vivo metabolite identification Rapid Communications in Mass Spectrometry ·Kevin P. Bateman, José Castro‐Perez, Mark Wrona, John P. Shockcor, Kate Yu, Renata M. Oballa, Deborah A. Nicoll‐Griffith	2007	204
2	‘All‐in‐One’ analysis for metabolite identification using liquid chromatography/hybrid quadrupole time‐of‐flight mass spectrometry with collision energy switching Rapid Communications in Mass Spectrometry ·Mark Wrona, Timo Mauriala, Kevin P. Bateman, Russell J. Mortishire‐Smith, Desmond O’Connor	2005	143
3	Discovery of 4-{1-[({1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl}carbonyl)amino]cyclopropyl}benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain Bioorganic & Medicinal Chemistry Letters ·John Colucci, Michael J. Boyd, Carl Berthelette, Jean-François Chiasson, Zhaoyin Wang, Yves Ducharme, R. W. Friesen, Mark Wrona, Jean-François Lévesque, Danielle Denis, Marie‐Claude Mathieu, Rino Stocco, Alex G. Therien, Patsy Clarke, Steve Rowland, Daigen Xu, Yongxin Han	2010	29
4	The Discovery of 4-{1-[({2,5-Dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic Acid (MK-2894), A Potent and Selective Prostaglandin E₂Subtype 4 Receptor Antagonist Journal of Medicinal Chemistry ·Marc Blouin, Yongxin Han, Jason D. Burch, Julie Farand, Christophe Mellon, Mireille Gaudreault, Mark Wrona, Jean-François Lévesque, Danielle Denis, Marie‐Claude Mathieu, Rino Stocco, Érika Vigneault, Alex G. Therien, Patsy Clark, Steve Rowland, Daigen Xu, Gary P. O’Neill, Yves Ducharme, R. W. Friesen	2010	29
5	Chemical Profiling of Ginseng Species and Ginseng Herbal Products Using UPLC/QTOF-MS Journal of the Brazilian Chemical Society ·Jimmy Yuk, Dhavalkumar Narendrabhai Patel, Giorgis Isaac, Kerri M. Smith, Mark Wrona, Hernando J. Olivos, Kate Yu	2016	25
6	Solution NMR Structure and X-ray Absorption Analysis of the C-Terminal Zinc-Binding Domain of the SecA ATPase Biochemistry ·Brian R. Dempsey, Mark Wrona, Jana M. Moulin, Gregory B. Gloor, Farideh Jalilehvand, Gilles Lajoie, Gary S. Shaw, Brian H. Shilton	2004	20
7	Novel Interconnections in Lipid Metabolism Revealed by Overexpression of Sphingomyelin Synthase-1 Journal of Biological Chemistry ·Gergana M. Deevska, P. Patrick Dotson, Alexander Karakashian, Giorgis Isaac, Mark Wrona, Samuel B. Kelly, Alfred H. Merrill, Mariana Nikolova‐Karakashian	2017	18
8	A novel series of potent and selective EP4 receptor ligands: Facile modulation of agonism and antagonism Bioorganic & Medicinal Chemistry Letters ·Michael J. Boyd, Carl Berthelette, Jean-François Chiasson, Patsy Clark, John Colucci, Danielle Denis, Yongxin Han, Jean-François Lévesque, Marie‐Claude Mathieu, Rino Stocco, Alex G. Therien, Steve Rowland, Mark Wrona, Daigen Xu	2010	18
9	Structure–activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP4 receptor Bioorganic & Medicinal Chemistry Letters ·Jason D. Burch, Michel Belley, Réjean Fortin, Denis Deschênes, M. Fusco Girard, John Colucci, Julie Farand, Alex G. Therien, Marie‐Claude Mathieu, Danielle Denis, Érika Vigneault, Jean-François Lévesque, Sébastien Gagné, Mark Wrona, Daigen Xu, Patsy Clark, Steve Rowland, Yongxin Han	2008	15
10	Development of an UPLC/MS–MS Method for Quantification of Intact IGF-I from Human Serum Bioanalysis ·Nikunj Tanna, Mary E. Lame, Mark Wrona	2019	15
11	Metabolic Profiling of Hoodia, Chamomile, Terminalia Species and Evaluation of Commercial Preparations Using Ultrahigh-Performance Liquid Chromatography Quadrupole-Time-of-Flight Mass Spectrometry Planta Medica ·Bharathi Avula, Yan‐Hong Wang, Giorgis Isaac, Jimmy Yuk, Mark Wrona, Kate Yu, Ikhlas A. Khan	2017	14
12	Development and application of sub‐2‐μm particle CO ₂ ‐based chromatography coupled to mass spectrometry for comprehensive analysis of lipids in cottonseed extracts Rapid Communications in Mass Spectrometry ·Carolina Salazar, Michael D. Jones, Drew Sturtevant, Patrick J. Horn, Janna L. Crossley, Khadiza Zaman, Kent D. Chapman, Mark Wrona, Giorgis Isaac, Norman W. Smith, Vladimir Shulaev	2017	13
13	Metabolite identification using an ion mobility enhanced data‐independent acquisition strategy and automated data processing Rapid Communications in Mass Spectrometry ·Tatiana Radchenko, Christopher J. Kochansky, Mark T. Cancilla, Mark Wrona, Russell J. Mortishire‐Smith, Jayne Kirk, Gordon J. Murray, Fabien Fontaine, Ismael Zamora	2020	13
14	Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor Bioorganic & Medicinal Chemistry Letters ·Jason D. Burch, Julie Farand, John Colucci, Claudio F. Sturino, Yves Ducharme, Richard W. Friesen, Jean-François Lévesque, Sébastien Gagné, Mark Wrona, Alex G. Therien, Marie‐Claude Mathieu, Danielle Denis, Érika Vigneault, Daigen Xu, Patsy Clark, Steve Rowland, Yongxin Han	2010	12
15	Microflow UPLC and High-Resolution MS as a Sensitive and Robust Platform for Quantitation of Intact Peptide Hormones Bioanalysis ·Zhuo Chen, Yun W. Alelyunas, Mark Wrona, Jonathan Kehler, Matthew Szapacs, Christopher A. Evans	2019	12
16	Integration of Microfluidic LC with HRMS for The Analysis of Analytes in Biofluids: Past, Present and Future Bioanalysis ·Paul Rainville, James Langridge, Mark Wrona, Ian D. Wilson, Robert S. Plumb	2015	11
17	Characterization of (16R) and (16S)-hydroxyroquefortine C; diastereomeric metabolites from Penicillium crustosum DAOM 215343 Tetrahedron Letters ·Laird A. Trimble, Mark W. Sumarah, Barbara A. Blackwell, Mark Wrona, J. David Miller	2011	10
18	An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry Journal of Visualized Experiments ·Catalin E. Doneanu, Jing Fang, Yun W. Alelyunas, Ying Yu, Mark Wrona, Wenxue Chen	2018	7
19	Coupling of Uhplc With Fast Fraction Collection–Microplate Scintillation Counting And Ms For Radiolabeled Metabolite Profiling Bioanalysis ·Tong Wei, Swapan K. Chowdhury, Mark Wrona, Kevin P. Bateman	2012	7
20	Intact mAb LC–MS for Drug Concentration from Pre-Clinical Studies: Bioanalytical Method Performance and in-Life Samples Bioanalysis ·John F. Kellie, Yun W. Alelyunas, Josh Albert, Nicole A. Schneck, Zhuo Chen, Caroline Sychterz, Ian B. Edwards, Henry Shion, Mark Wrona, Matthew Szapacs	2020	7

About Mark Wrona

Mark Wrona is a scholar working on Spectroscopy, Complementary and alternative medicine, Pharmacology, Biochemistry and Toxicology, having authored 33 papers that have together received 642 indexed citations. Recurring topics across this work include Analytical Chemistry and Chromatography (9 papers), Metabolomics and Mass Spectrometry Studies (9 papers), Mass Spectrometry Techniques and Applications (9 papers), Inflammatory mediators and NSAID effects (5 papers), Protein purification and stability (4 papers), Synthesis of β-Lactam Compounds (4 papers), Natural product bioactivities and synthesis (3 papers) and Traditional Chinese Medicine Analysis (3 papers). The work is most often cited by research in Spectroscopy (261 citations), Pharmacology (63 citations), Pharmacology (98 citations), Molecular Biology (382 citations) and Analytical Chemistry (50 citations). Mark Wrona has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Kevin P. Bateman, Kate Yu, Russell J. Mortishire‐Smith, Renata M. Oballa, José Castro‐Perez, Deborah A. Nicoll‐Griffith, John P. Shockcor, Timo Mauriala, Desmond O’Connor and Giorgis Isaac. Their work appears in journals such as Planta Medica, Bioanalysis, Rapid Communications in Mass Spectrometry, Bioorganic & Medicinal Chemistry Letters and Drug Metabolism and Pharmacokinetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact